Latest General Surgery News

Five cases of an unusual primary benign stromal tumor designated as hemangioblastoma-like clear cell stromal tumor of the lung are presented. The patients are 4 women and 1 man between the ages of 39 and 52 years of age (average: 45.5 y). The patients presented with nonspecific symptoms of cough, chest... Read more
Published on: 2020-05-29
Source: THE AMERICAN JOURNAL OF SURGICAL PATHOLOGY - most emailed articles
The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a corticosteroid and long-acting beta-2 agonist indicated for the treatment of asthma and COPD.  The Propeller platform includes a sensor that is attached to the inhaler.... Read more
Published on: 2020-05-28
Source: MPR THE RIGHT DOSE OF INFORMATION - home
By: Steve Duffy
Published on: 2020-05-28
Source: جميع الحقوق محفوظة – وزارة الصحة أنباء من وزارة الصحة
The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab; Bristol Myers Squibb) plus Yervoy (ipilimumab; Bristol Myers Squibb) and 2 cycles of platinum-doublet chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic... Read more
Published on: 2020-05-28
Source: MPR THE RIGHT DOSE OF INFORMATION - home
By: Diana Ernst, RPh
The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES. The post Mepolizumab Gets Priority Review for Hypereosinophilic Syndrome appeared first on MPR.... Read more
Published on: 2020-05-28
Source: MPR THE RIGHT DOSE OF INFORMATION - home
By: Steve Duffy
The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES. The post Mepolizumab Gets Priority Review for Hypereosinophilic Syndrome appeared first on MPR.... Read more
Published on: 2020-05-28
Source: MPR THE RIGHT DOSE OF INFORMATION - drugs in the pipeline
By: Steve Duffy
Treatment with ofatumumab (Novartis) was associated with a greater proportion of patients with relapsing forms of multiple sclerosis (RMS) achieving no evidence of disease activity (NEDA-3), compared with those who received teriflunomide, according to post hoc analysis of the phase 3 ASCLEPIOS trials. The post Ofatumumab Bests Teriflunomide in Halting... Read more
Published on: 2020-05-28
Source: MPR THE RIGHT DOSE OF INFORMATION - home
By: Steve Duffy
Treatment with ofatumumab (Novartis) was associated with a greater proportion of patients with relapsing forms of multiple sclerosis (RMS) achieving no evidence of disease activity (NEDA-3), compared with those who received teriflunomide, according to post hoc analysis of the phase 3 ASCLEPIOS trials. The post Ofatumumab Bests Teriflunomide in Halting... Read more
Published on: 2020-05-28
Source: MPR THE RIGHT DOSE OF INFORMATION - drugs in the pipeline
By: Steve Duffy
Antibiotics were no better than placebo for acute mild uncomplicated diverticulitis.... Read more
Published on: 2020-05-28
Source: NEJM JOURNAL WATCH - specialty: hospital medicine
By: John P. Haydek, MD,Daniel D. Dressler, MD, MSc, SFHM, FACP
Many patients showed improvement with noninvasive ventilation and prone positioning.... Read more
Published on: 2020-05-28
Source: NEJM JOURNAL WATCH - specialty: hospital medicine
By: Patricia Kritek, MD
  • Other News

    by specialization

  • Other News

    by specialization

Translate »